Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries | Ca-A Cancer Journal for Clinicians | 2021 | 11.2K |
Cancer Statistics, 2021 | Ca-A Cancer Journal for Clinicians | 2021 | 4K |
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary | Neuro-Oncology | 2021 | 708 |
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies | Cell Host and Microbe | 2021 | 569 |
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition | Cell Host and Microbe | 2021 | 525 |
Cancer statistics for the year 2020: An overview | International Journal of Cancer | 2021 | 493 |
Japanese gastric cancer treatment guidelines 2018 (5th edition) | Gastric Cancer | 2021 | 484 |
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization | Cell Host and Microbe | 2021 | 423 |
Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications | Lancet Regional Health - Europe, The | 2021 | 284 |
RNA in cancer | Nature Reviews Cancer | 2021 | 279 |
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization | Cell Host and Microbe | 2021 | 277 |
Broadening horizons: the role of ferroptosis in cancer | Nature Reviews Clinical Oncology | 2021 | 272 |
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 244 |
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study | Lancet Oncology, The | 2021 | 240 |
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines | Cell Host and Microbe | 2021 | 225 |
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite | Cell Host and Microbe | 2021 | 215 |
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood | Nature Reviews Clinical Oncology | 2021 | 204 |
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma | International Journal of Gynecological Cancer | 2021 | 203 |
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization | Cell Host and Microbe | 2021 | 198 |
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2021 | 180 |
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021 | Journal of the National Comprehensive Cancer Network: JNCCN | 2021 | 177 |
The variant gambit: COVID-19's next move | Cell Host and Microbe | 2021 | 164 |
Exploring the NK cell platform for cancer immunotherapy | Nature Reviews Clinical Oncology | 2021 | 161 |
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types | Annals of Oncology | 2021 | 158 |
Liquid biopsy enters the clinic - implementation issues and future challenges | Nature Reviews Clinical Oncology | 2021 | 158 |